Srivatava, S., Srivastava, A.
Fabrication and Evaluation of matrix type Transdermal Patches of Primaquine Phosphate with different ratio of eudragit-L100 and S-100 combination by the solvent evaporation technique. All the patches have been evaluated for their Physiochemical properties was studied by infrared Spectroscopy. Formulation F1 was found best among the all formulation on basis maximum in-vitro release, drug content and folding endurance i.e. 4.711, 99% ± 0.2, 26 ± 2. Other parameters like moisture content, moisture uptake, surface pH was found 1.32 ± 0.38, 3.14 ± 0.2 and 8.9 respectively. Hence F1 formulation was used to incorporate penetration enhancer labrafac™ PD, labrafil® 1944CS and lauroglucol™ FCC. By using this three penetration enhancer nine formulation L1 to L9 was fabricated to increasing volume of 0.5ml, 1.0ml, 1.5 ml. All the formulation was tested for thickness, weight variation, folding endurance, surface pH, moisture content and %drug content. L6 was showing maximum drug content and folding endurance as 99.8%, 28 respectively. The in-vitro release study was carried out with Shimadzu HPLC system. L6 formulation showed the best release value 75.47% in 24hr, emerging to be ideal formulations for Primaquine Phosphate and the mechanism of release was fitted to peppas kinetic models. The formulated transdermal patches increase antimalarial activity and reduced the adverse drug reactions gastrointestinal distress, nausea and methemoglobinemia with cyanosis.
Primaquine Phosphate, EudragitL-100, EudragitS-100, Solvent Casting Technique, Plasticizer, Different enhancer
Cite This Article
Srivatava, S., Srivastava, A. (2016). Fabrication and Evaluation of Transdermal Patches of Primaquine Phosphate, International Journal for Pharmaceutical Research Scholars (IJPRS), 5(2), 151-161.